Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy

A new therapy strategy for relapsing patients who have received trastuzumab treatment urgently needs to be explored. HER2-specific chimeric antigen receptor (CAR)-expressing NK cells are being rapidly developed for solid tumor therapy, as they have many advantages over HER2-CAR-T cells. Endogenous s...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Wenjiao, Chen, Jiaxin, Hou, Wenqing, Chen, Junsheng, Xiong, Ying, Li, Hongyan, Qi, Xin, Xu, Hui, Xie, Zuoquan, Li, Mingfeng, Zhang, Xiaomin, Li, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094803/
https://www.ncbi.nlm.nih.gov/pubmed/37047817
http://dx.doi.org/10.3390/ijms24076843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094803/
https://www.ncbi.nlm.nih.gov/pubmed/37047817
http://dx.doi.org/10.3390/ijms24076843

Ejemplares similares